ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension
Zolgensma is a gene therapy medicine for treating spinal muscular atrophy, a serious condition of the nerves that causes muscle wasting and weakness. Brand Name: ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion Initial U.S. Approval: 2019
Home | onasemnogene abeparvovec-xioi suspension
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion
Onasemnogene abeparvovec-xioi injection is used to treat spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
ZOLGENSMA is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
Limitations of Use
• The safety and effectiveness of repeat administration of ZOLGENSMA have not been evaluated.
• The use of ZOLGENSMA in patients with advanced SMA (e.g.,complete paralysis of limbs, permanent ventilator dependence) has not been evaluated.
Onasemnogene abeparvovec, sold under the brand name Zolgensma, is a gene therapy used to treat spinal muscular atrophy (SMA), a disease causing muscle function loss in children. It involves a one-time infusion of the medication into a vein. It works by providing a new copy of the SMN gene that produces the SMN protein.
In the United States, onasemnogene abeparvovec is indicated for the treatment of people less than two years of age with spinal muscular atrophy with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
The treatment is approved in the United States and certain other countries for use in children with spinal muscular atrophy up to the age of two, including at the presymptomatic stage of the disease. In the European Union and Canada, it is indicated for the treatment of people with spinal muscular atrophy who either have a clinical diagnosis of spinal muscular atrophy type 1 or have up to three copies of the SMN2 gene.
Drug (Brand / Generic): ZOLGENSMA / onasemnogene abeparvovec-xioi
Current Indications: spinal muscular atrophy (SMA)
Marketed by:: Novartis Gene Therapies
Approval Date: 2019
ZOLGENSMA is a suspension for intravenous infusion, supplied as single-use vials.
ZOLGENSMA is provided in a kit containing 2 to 14 vials, as a combination 2 vial fill volumes (either 5.5 mL or 8.3 mL). All vials have a nominal
concentration of 2.0 × 1013 vector genomes (vg) per mL. Each vial of OLGENSMA contains an extractable volume of not less than either 5.5 mL or
8.3 mL.
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension ”. Confirmation of the order for ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – ZOLGENSMA
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha.
ZOLGENSMA Sourcing & Delivery
Alleviare India specializes in sourcing and supplying ZOLGENSMA, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of ZOLGENSMA in India.
How much does ZOLGENSMA cost in the India?
Kindly reach out to us for ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import ZOLGENSMA to India?
To import onasemnogene abeparvovec-xioi ZOLGENSMA, patients or government hospitals can place an order on behalf of the patients.
The following documentation is required for the import process:
- Valid prescription from a qualified doctor.
- Patients’ diagnostic reports.
- Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
- Valid prescription from the doctor.
- Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is ZOLGENSMA available in India?
ZOLGENSMA onasemnogene abeparvovec-xioi is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of ZOLGENSMA (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for ZOLGENSMA availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is onasemnogene abeparvovec-xioi available in India?
The US Food and Drug Administration (FDA) on May 24, 2019 approved onasemnogene abeparvovec, a drug for the treatment of spinal muscular atrophy (SMA). The drug, developed by the Swiss drugmaker Novartis, has been marketed under the trade name Zolgensma.
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension . The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension , they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
